Cydex Pharmaceuticals, Inc.

Merck + Co., Inc.

University of Kansas

Merck Sharp + Dohme Corp.

Nps Pharmaceuticals, Inc.

James D Pipkin

Gerold L Mosher

Douglas B Hecker

Rupert O Zimmerer

Diane O Thompson

Gerald S Rork

Roger A Rajewski

Stephen G Machatha

Beau Mainous

David Monteith

Susan K Heimbecher

Naomi Esaki

Thomas B Marriott

John L Haslam

Lian G Rajewski

John M Siebert

David S Wells

Susan Heimbecher

Cosmetic and dietary supplement compositions containing silymarin and sulfoalkyl ether cyclodextrin, particularly sulfobutyl ether cyclodextrin, are described. The compositions and methods are useful in reducing appearance of facial redness in rosacea-prone skin, rejuvenating skin, preventing skin aging, inhibiting oxidative stress in epidermal and dermal cells, increasing collagen production, reducing the likelihood of skin cancer, treating or reducing liver damage from a toxin, or treating a liver disease.

Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same

The present invention is directed to methods of treating nasal and/or ophthalmic diseases, symptoms, or disorders that are therapeutically responsive to corticosteroid therapy by delivering aqueous solution formulations comprising a corticosteroid to nasal and ophthalmic tissues. The invention is also directed to methods, systems, devices, and compositions for delivering aqueous solution formulations comprising a corticosteroid and an antihistamine to nasal and ophthalmic tissues.

Nasal and ophthalmic delivery of aqueous corticosteroid solutions

An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.

DPI formulation containing sulfoalkyl ether cyclodextrin

An aqueous composition of latanoprost and SAE-CD is provided. The composition possesses improved stability over otherwise similar compositions excluding SAE-CD. Methods of and systems for treating disease, disorders, conditions or symptoms of the eye that are therapeutically responsive to latanoprost are also provided.

Composition containing sulfoalkyl ether cyclodextrin and latanoprost

The present disclosure is directed to pharmaceutical compositions comprising a nitrogen mustard and a cyclodextrin derivative, and methods of making and using the same.

Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same

The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.

Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same

An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid

A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.

Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof

An aqueous composition of latanoprost and SAE-CD is provided. The composition possesses improved stability over otherwise similar compositions excluding SAE-CD. Methods of and systems for treating diseases, disorders, conditions or symptoms of the eye that are therapeutically responsive to latanoprost are also provided.

Growing community of inventors

Lawrence, KS, United States of America

James D Pipkin